Avicanna Inc., a biopharmaceutical company specializing in cannabinoid-based products, announced that board member Eileen McCormack has resigned effective May 1, 2026, before the upcoming annual general and special shareholders meeting on May 7. McCormack was not up for re-election at this meeting. Avicanna continues to focus on its development and commercialization of medical cannabis and pharmaceutical products globally, with multiple business pillars including medical cannabis formularies, patient care platforms, pharmaceutical pipelines, and active pharmaceutical ingredients. This board change is part of the company’s ongoing governance updates as it advances its strategic goals in the cannabinoid market.
Perplexity AI CEO Aravind Srinivas shared lessons from Nvidia's Jensen Huang and Tesla's Elon Musk, highlighting Huang's mindset of running Nvidia as if it could fail within 30 days despite its $5 trillion valuation and advanced technology. Srinivas ...
Meta Platforms introduced an AI-powered feature called "AI Mode" within Facebook Search, which uses Meta's AI model Muse Spark to provide answers from public content rather than traditional search results. This innovation could generate over $10 bill...
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
